Healthcare Industry News: HSMN NewsFeed
News Release - May 2, 2017
ViewRay Showcases World's First Commercially Available MRI-Guided Linac System at Leading European Radiation Oncology MeetingClinical Presentations Highlight Benefits of MRI-Guidance for Pancreatic, Gastrointestinal, and Prostate Cancers
Cancer Survivor Bibian Mentel, MRIdian Patient and Gold Medal Paralympian, Shares Her Story
CLEVELAND, May 2, 2017 -- (Healthcare Sales & Marketing Network) -- ViewRay, Inc. (Nasdaq: VRAY) announced today that the company will showcase its next generation MRI-guided radiation therapy solution, MRIdian Linac, at ESTRO 36, the annual meeting of the European Society for Radiotherapy and Oncology, being held May 5-9, 2017 in Vienna, Austria. The MRIdian Linac is available for sale and clinical use in the United States and Europe. Visitors to the booth can see the MRIdian Linac's compact design, enabled by the company's patented magnetic shielding and radiofrequency cloaking technologies, allowing it to fit into standard linac vaults.
ViewRay is the only commercially available system capable of delivering on-table adaptive radiation therapy using MRI guidance. To date, more than 1,500 of these adaptive treatment sessions have been performed using the MRIdian system, in each case reshaping the radiation dose while the patient is on the table to match changes in his or her anatomy.
MRIdian will be the subject of 10 presentations as part of ESTRO's Scientific Program covering clinical experience with MRI-guidance in the treatment of cancers including pancreas, gastrointestinal, and prostate. These MRIdian talks will discuss on-table adaptive delivery, stereotactic body radiation therapy (SBRT), inter-fraction motion management, patient specific quality assurance and more. A full list of MRIdian-focused Scientific Program presentations is available at http://www.viewray.com/estro_2017.htm.
Throughout the conference ViewRay booth attendees can hear firsthand clinical experience from five MRIdian users at three different institutions who will present on topics including implementation of an MRI-guided radiation therapy program and on-table adaptive treatment delivery. A detailed schedule of presenters, dates and times is available at http://www.viewray.com/estro_2017.htm.
On Sunday, May 7, 2017 at 1:15 p.m. Central European Time in Room Lehar 1-3, ViewRay will host a symposium titled "MRI-Guided RT with MRIdian: Perspectives from Installation to Clinical Use," which will feature presentations from various MRIdian centers. A video replay of the symposium will be available via ViewRay's website in the weeks following ESTRO.
On Monday, May 8 at 1:15 p.m., visitors to ViewRay's booth #400 can hear Gold Medal Paralympian Bibian Mentel discuss her snowboarding career, cancer journey and MRIdian treatment experience.
"We believe the ability to reshape the dose will make MRI-guided radiation therapy the new standard of care in cancer treatment," said Chris A. Raanes, ViewRay president and CEO. "We're excited to showcase the world's only commercially available MRI-guided Linac system at this year's ESTRO and to have so many MRIdian users present their clinical experience and patient outcomes to date."
ViewRay®, Inc. (Nasdaq: VRAY), designs, manufactures and markets the MRIdian® radiation therapy system. MRIdian integrates MRI technology, radiation delivery and proprietary software to locate, target and track the position and shape of soft-tissue tumors during radiation. ViewRay believes this combination of enhanced visualization and accuracy will significantly improve outcomes for patients.
ViewRay and MRIdian are registered trademarks of ViewRay, Inc.
Forward Looking Statements:
This press release contains forward-looking statements. Statements in this press release that are not purely historical are forward-looking statements. Such forward-looking statements include, among other things, the content and timing of presentations at ESTRO 36 and references to MRI-guided radiation therapy becoming a new standard of care in cancer treatment. Actual results could differ from those projected in any forward-looking statements due to numerous factors. Such factors include, among others, the ability to raise the additional funding needed to continue to pursue ViewRay's business and product development plans, the inherent uncertainties associated with developing new products or technologies, competition in the industry in which ViewRay operates and overall market conditions. These forward-looking statements are made as of the date of this press release, and ViewRay assumes no obligation to update the forward-looking statements, or to update the reasons why actual results could differ from those projected in the forward-looking statements, except as required by law. Investors should consult all of the information set forth herein and should also refer to the risk factor disclosure set forth in the reports and other documents ViewRay files with the SEC available at www.sec.gov.
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.